News & Updates

Bevacizumab + EGFR-TKI improves OS in EGFR-mutated NSCLC with leptomeningeal metastases
Bevacizumab + EGFR-TKI improves OS in EGFR-mutated NSCLC with leptomeningeal metastases
20 Mar 2024 bySarah Cheung

Adding bevacizumab to an EGFR tyrosine kinase inhibitor (TKI) improves overall survival (OS) in adult patients with EGFR-mutated non-small-cell lung cancer (NSCLC) and leptomeningeal metastases (LMs), according to a single-centre, retrospective, real-world study in China. OS was, however, similar between patients on chemotherapy plus EGFR-TKI and those on EGFR-TKI monotherapy.

 

Bevacizumab + EGFR-TKI improves OS in EGFR-mutated NSCLC with leptomeningeal metastases
20 Mar 2024
Broaden screening in patients with TB or HBV, says study
Broaden screening in patients with TB or HBV, says study
17 Mar 2024 byStephen Padilla

Patients with hepatitis B virus (HBV) infection are at heightened risk of latent tuberculosis (TB), while those with latent TB are also at increased risk of HBV infection, reveals a study. Notably, the risk of co-infection is highest among Asians and those born in high-incidence countries.

Broaden screening in patients with TB or HBV, says study
17 Mar 2024
Long COVID a driver of unemployment
Long COVID a driver of unemployment
14 Mar 2024 byAudrey Abella

Long COVID may have contributed to reduced participation in the UK labour market, a cohort study suggests.

Long COVID a driver of unemployment
14 Mar 2024
Negative mood worsens dyspnoea in COPD
Negative mood worsens dyspnoea in COPD
10 Mar 2024 byStephen Padilla

A negative affective state can aggravate dyspnoea in patients with chronic obstructive pulmonary disease (COPD), a study has shown. This suggests that reducing the likelihood of negative mood or improving the mood can help in managing morbidities associated with dyspnoea in COPD.

Negative mood worsens dyspnoea in COPD
10 Mar 2024
Severe COVID-19 rare in PrEP-treated SARDs patients
Severe COVID-19 rare in PrEP-treated SARDs patients
08 Mar 2024 byStephen Padilla

Breakthrough COVID-19 is not uncommon following pre-exposure prophylaxis (PrEP) with tixagevimab/cilgavimab among patients with systemic autoimmune rheumatic diseases (SARDs), reports a recent study. However, most of the infections in this high-risk population are not severe.

Severe COVID-19 rare in PrEP-treated SARDs patients
08 Mar 2024
Pulse vs nonpulse corticosteroid: Which is better against IPF?
Pulse vs nonpulse corticosteroid: Which is better against IPF?
07 Mar 2024

Patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) who received a pulse dose of corticosteroids do not appear to have longer survival than those who received conventional nonpulse dose of corticosteroids, results of a study have shown.

Pulse vs nonpulse corticosteroid: Which is better against IPF?
07 Mar 2024